LUVERIS Powder and solvent for solution for injection Ref.[8845] Active ingredients: Lutropin alfa

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: Merck Europe B.V., Gustav Mahlerplein 102, 1082 MA Amsterdam, The Netherlands

Product name and form

Luveris 75 IU powder and solvent for solution for injection.

Pharmaceutical Form

Powder and solvent for solution for injection (powder for injection).

Appearance of the powder: white lyophilised pellet

Appearance of the solvent: clear colourless solution

The pH of the reconstituted solution is 7.5 to 8.5.

Qualitative and quantitative composition

One vial contains 75 IU of lutropin alfa*.

* recombinant human luteinising hormone (r-hLH) produced in genetically engineered Chinese hamster ovary (CHO) cells by recombinant DNA technology

For the full list of excipients, see section 6.1.

Active Ingredient

Lutropin alfa is a recombinant human Luteinising Hormone (r-hLH). Luteinising hormone (LH) and follicle stimulating hormone (FSH) are secreted from the anterior pituitary gland in response to gonadotropin-releasing hormone (GnRH) and play a complementary role in follicle development and ovulation. In theca cells, LH stimulates the secretion of androgens that are transferred to granulosa cells to be converted to estradiol (E2) by aromatase. In granulosa cells, FSH stimulates the development of ovarian follicles, while LH action is involved in follicle development, steroidogenesis and maturation.

List of Excipients

Powder:

Sucrose
Disodium phosphate dihydrate
Sodium dihydrogen phosphate monohydrate
Polysorbate 20
Phosphoric acid, concentrated (for pH adjustment)
Sodium hydroxide (for pH adjustment)
L-methionine
Nitrogen

Solvent:

Water for injection

Pack sizes and marketing

The powder is packaged in 3 mL neutral colourless glass (type I) vials. The vials are sealed with bromobutyl stoppers protected by aluminium seal rings and flip-off caps. The solvent is packaged in 2 or 3 mL neutral colourless glass (type I) vials with a Teflon-coated rubber stopper.

Packs of 1, 3 or 10 vials with the corresponding number of solvent vials. Not all pack sizes may be marketed.

Marketing authorization holder

Merck Europe B.V., Gustav Mahlerplein 102, 1082 MA Amsterdam, The Netherlands

Marketing authorization dates and numbers

EU/1/00/155/004
EU/1/00/155/005
EU/1/00/155/006

Date of first authorisation: 29 November 2000
Date of latest renewal: 24 January 2006

Drugs

Drug Countries
LUVERIS Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, United Kingdom, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.